Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Several other research analysts have also recently weighed in on the company. Lake Street Capital decreased their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th.

Ekso Bionics Stock Performance

EKSO stock opened at $0.62 on Thursday. The company has a market capitalization of $13.64 million, a P/E ratio of -0.95 and a beta of 1.47. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The company has a 50-day simple moving average of $0.66 and a 200 day simple moving average of $0.92. Ekso Bionics has a fifty-two week low of $0.50 and a fifty-two week high of $2.35.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter last year, the business earned ($0.24) earnings per share. Sell-side analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.